Literature DB >> 17219340

[Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].

S Uen1, I Un, R Fimmers, H Vetter, T Mengden.   

Abstract

OBJECTIVE: To examine the effect of candesartan cilexetil with hydrochlorothiazide (6 mg and 12.5 mg, respectively) on blood pressure and ST-segment depression during daily life of patients with treated but not controlled arterial hypertension (blood pressure taken at doctor's practice (3)140/90 mmHg, despite being on at least two antihypertensive drugs) PATIENTS AND METHODS: 51 patients (45 men, 17 women) with treated but reportedly uncontrolled hypertension were placed on self-measurement of blood pressure for 4 weeks of a run-in period and 8 weeks as a follow-up period. Combined 24-hour automatic blood pressure measurement (ABPM) and electrocardiography were done at the end of the run-in and the follow-up periods. Ten patients proved to be normotensive according to the self-measurement and ABPM after the run-in period (group A), while 41 were still uncontrolled according to both methods (group B). In group B the least efficacious component of the antihypertensive medication was replaced by candesartan with hydrochlorothiazide (C + HCT) and any changes in blood pressure and ST-segment depression analysed after 8 weeks of follow-up in both groups.
RESULTS: In group A no significant blood pressure change was observed between run-in- and follow-up periods. But in group B (n=41) the self-measured systolic blood pressure had significantly decreased (155/84 mmHg compared with [vs] 147/81 mmHg; p<0.0073) as had the systolic 24-h ABPM (148/81 mmHg vs 137/753 mmHg; p<0.0015) after C + HCT had replaced the previous noneffective medication. After the run-in period 15 patients of group B had ST-segment depression (1 mm of horizontal or descending depression for at least 1 minute). In 16 other patients of group B and in all patients of group A no ST depressions were recorded. At the end of the follow-up period significant reduction of mean ischemic burden per patient (106 vs 72 minutes), of total ischemic events (228 vs 153) and of mean duration of ST depression (372 vs 210 seconds) had occurred.
CONCLUSIONS: Replacing candesartan + hydrochlorothiazide for previously ineffective antihypertensive drugs in patients with uncontrolled arterial hypertension significantly reduced both blood pressure and ST-segment depression during daily life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17219340     DOI: 10.1055/s-2007-959292

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  5 in total

1.  Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.

Authors:  Reinhard Ketelhut; Peter Bramlage
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  An overview of candesartan in clinical practice.

Authors:  Zeeshan Khawaja; Christopher S Wilcox
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-08

3.  Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).

Authors:  Gerd Bönner; Bernhard Landers; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2011-02-17

4.  Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon.

Authors:  Thomas Mengden; Reinhold Hübner; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2011-12-12

Review 5.  Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.

Authors:  Thomas Mengden; Sakir Uen; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2009-12-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.